Reveal Biosciences attended Biocom’s recent CRO seminar on Pre-Clinical Efficacy Models for Immuno-Oncology Studies in Humanized Mice. Pharmatest Services and Taconic Biosciences hosted this informative seminar where they presented on humanized immune system models for
Reveal Biosciences Founder and CEO, Dr. Claire Weston, was recently featured in the Tech Spotlight interview series. This interview covered topics such as the inception of Reveal Biosciences, the future impact of AI on pathology,
Casey Laris, CTO of Reveal Biosciences, lead a webinar entitled “Revolutionize Pathology using Artificial Intelligence” as part of the Science Exchange Webinar Series. Highlights from this webinar include: Reveal Biosciences specializes in data powered pathology.
The hematoxylin and eosin (H&E) stain has long been an essential tool in the pathologist’s arsenal. Positively-charged hematoxylin and negatively-charged eosin bind to different substances within a tissue sample. This allows pathologists to clearly view
Athena, a voice for professional women in STEM in Southern California, recently became a signatory of the United Nations Global Compact. Athena joins over 9,933 companies in 160 countries focused on aligning their strategies and
Orthotopic Patient-Derived Xenografts (PDX) Despite the rise of personalized approaches to the treatment of cancer, translating these therapies into a clinical setting still poses an exceptional challenge. This is highlighted in drug development where research